Breaking Through Standard Method Validation With the Corona CAD Universal HPLC Detector
Sponsored By: ESA Biosciences, Inc.
Register now for this on-demand webcast, which originally aired on February 20, 2008, and learn how a new universal HPLC detector, the Corona CAD, has been evaluated for the development of validated methods by several pharmaceutical and biotech companies. Details of the validation of methods will be presented for two sample sets: accurate measurements of a traditional small molecule drug substance, and impurity determinations of a peptide drug product formulated in a mixture of lipids and phospholipids. The Corona CAD methods were rigorously and successfully validated against standard method validation criteria. The data presented here demonstrate that not only can validated methods be developed using the Corona CAD, but that the Corona CAD enables previously difficult analyses, saving time and resources.
MODERATOR: Agnes Shanley, Editor in Chief, Pharmaceutical Manufacturing
Agnes Shanley is Editor in Chief of Putman Media’s Pharmaceutical Manufacturing publication and website. Prior to joining Putman Media, Shanley has covered the pharmaceutical, biotech, and chemical industries extensively for publications that include Chemical Engineering, Chemical Processing, Chemical Business, Chemical Marketing Reporter, and the Homeland Defense Journal. Shanley received a B.A. in liberal arts from Barnard College, Columbia University, and a B.S. in chemistry and life sciences from the City University of New York.
SPEAKER: Dr. Asa, Marketing Director, ESA Biosceinces, Inc.
Dr. Asa is the Marketing Director for ESA Biosceinces, Inc. and is responsible for the sales and marketing of the revolutionary Corona CAD universal HPLC detector.
Previously he was the Marketing Manager for Biopharma at Tecan Inc. and a Sr. Scientist for Becton-Dickinson where he developed a series of products in areas ranging from molecular and cellular assays to ADME-Tox. Dr. Asa received his B.S. in Honors Biology from the University of Michigan-Flint in 1986 and his PhD in Biochemistry from the University of Illinois in 1991. His postdoctoral studies included work at Glycomed, Inc. and the Upjohn Company.